Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

DEK-CAN molecular monitoring of myeloid malignancies could aid therapeutic stratification.

Garçon L, Libura M, Delabesse E, Valensi F, Asnafi V, Berger C, Schmitt C, Leblanc T, Buzyn A, Macintyre E.

Leukemia. 2005 Aug;19(8):1338-44.

PMID:
15973457
2.
3.

t(6;9)(p22;q34)/DEK-NUP214-rearranged pediatric myeloid leukemia: an international study of 62 patients.

Sandahl JD, Coenen EA, Forestier E, Harbott J, Johansson B, Kerndrup G, Adachi S, Auvrignon A, Beverloo HB, Cayuela JM, Chilton L, Fornerod M, de Haas V, Harrison CJ, Inaba H, Kaspers GJ, Liang DC, Locatelli F, Masetti R, Perot C, Raimondi SC, Reinhardt K, Tomizawa D, von Neuhoff N, Zecca M, Zwaan CM, van den Heuvel-Eibrink MM, Hasle H.

Haematologica. 2014 May;99(5):865-72. doi: 10.3324/haematol.2013.098517. Epub 2014 Jan 17.

4.

Establishment of a novel human myeloid leukaemia cell line (FKH-1) with t(6;9)(p23;q34) and the expression of dek-can chimaeric transcript.

Hamaguchi H, Nagata K, Yamamoto K, Fujikawa I, Kobayashi M, Eguchi M.

Br J Haematol. 1998 Sep;102(5):1249-56.

PMID:
9753053
5.

The prognostic value of MLL-AF9 detection in patients with t(9;11)(p22;q23)-positive acute myeloid leukemia.

Scholl C, Schlenk RF, Eiwen K, Döhner H, Fröhling S, Döhner K; AML Study Group..

Haematologica. 2005 Dec;90(12):1626-34.

6.

Relevance of presenting white blood cell count and kinetics of molecular remission in the prognosis of acute myeloid leukemia with CBFbeta/MYH11 rearrangement.

Martín G, Barragán E, Bolufer P, Chillón C, García-Sanz R, Gómez T, Brunet S, González M, Sanz MA.

Haematologica. 2000 Jul;85(7):699-703.

7.

Prospective monitoring of minimal residual disease in acute myeloid leukemia with inversion(16) by CBFbeta/MYH11 RT-PCR: implications for a monitoring schedule and for treatment decisions.

Laczika K, Mitterbauer G, Mitterbauer M, Knöbl P, Schwarzinger I, Greinix HT, Rabitsch W, Fonatsch C, Mannhalter C, Lechner K, Jaeger U.

Leuk Lymphoma. 2001 Sep-Oct;42(5):923-31.

PMID:
11697647
8.

The kinetics of relapse in DEK-NUP214-positive acute myeloid leukemia patients.

Ommen HB, Touzart A, MacIntyre E, Kern W, Haferlach T, Haferlach C, Tobal K, Hokland P, Schnittger S.

Eur J Haematol. 2015 Nov;95(5):436-41. doi: 10.1111/ejh.12511. Epub 2015 Mar 13.

PMID:
25605311
9.
10.

Fluorescence in situ hybridization: a highly efficient technique of molecular diagnosis and predication for disease course in patients with myeloid leukemias.

Amare PS, Baisane C, Saikia T, Nair R, Gawade H, Advani S.

Cancer Genet Cytogenet. 2001 Dec;131(2):125-34.

PMID:
11750052
11.

Molecular disease eradication is a prerequisite for long-term remission in patients with t(8;21) positive acute myeloid leukemia: a single center study.

Mitterbauer M, Mitterbauer-Hohendanner G, Sperr WR, Kalhs P, Greinix HT, Fonatsch C, Haas OA, Jäger U, Mannhalter C, Lechner K.

Leuk Lymphoma. 2004 May;45(5):971-7.

PMID:
15291357
12.
13.

[Analysis of DEK-CAN fusion gene expression in acute myeloid leukemia patients with 6; 9 chromosome translocation].

Wang YL, Wang T, Xu F, Gang Y, Wang J.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2006 Apr;14(2):232-6. Chinese.

PMID:
16638187
14.
15.

Assessment of residual disease in acute leukemia by means of polymerase chain reaction.

Ruiz-Argüelles GJ, Garcés-Eisele J, Reyes-Núñez V, Pérez-Romano B, Ruiz-Argüelles A, Ramírez-Cisneros FJ, López-Martínez B, López-Tapia JD, Rivadeneyra-Espinoza L.

Rev Invest Clin. 2000 Mar-Apr;52(2):118-24.

PMID:
10846434
16.

Real-time quantitation of minimal residual disease in inv(16)-positive acute myeloid leukemia may indicate risk for clinical relapse and may identify patients in a curable state.

Buonamici S, Ottaviani E, Testoni N, Montefusco V, Visani G, Bonifazi F, Amabile M, Terragna C, Ruggeri D, Piccaluga PP, Isidori A, Malagola M, Baccarani M, Tura S, Martinelli G.

Blood. 2002 Jan 15;99(2):443-9.

17.
19.

Identification of a novel and myeloid specific role of the leukemia-associated fusion protein DEK-NUP214 leading to increased protein synthesis.

Ageberg M, Drott K, Olofsson T, Gullberg U, Lindmark A.

Genes Chromosomes Cancer. 2008 Apr;47(4):276-87. doi: 10.1002/gcc.20531.

PMID:
18181180
20.

Persistence of the AML1/ETO fusion transcript in patients treated with allogeneic bone marrow transplantation for t(8;21) leukemia.

Jurlander J, Caligiuri MA, Ruutu T, Baer MR, Strout MP, Oberkircher AR, Hoffmann L, Ball ED, Frei-Lahr DA, Christiansen NP, Block AM, Knuutila S, Herzig GP, Bloomfield CD.

Blood. 1996 Sep 15;88(6):2183-91.

Supplemental Content

Support Center